Mitotic kinesin inhibitors

1. A compound according to Formula I:

is phenyl;

X is: C(R 4 ) 2 4 ;

a is independently 0 or 1; b is independently 0 or 1; m is independently 0, 1 or 2; n is independently 0, 1, 2, 3 or 4;

R 1 and R 2 are independently selected from: H, CF 3 , oxo, OH, halo, CN, NH 2 , NO 2 , (C═O) a O b (C 1 -C 10 )alkyl, (C═O) a O b (C 2 -C 10 )alkenyl, (C═O) a O b (C 2 -C 10 )alkynyl, (C═O) a O b (C 3 -C 6 )cycloalkyl, (C═O) a O b (C 0 -C 6 )alkylene-aryl, (C═O) a O b (C 0 -C 6 )alkylene-N(R b ) 2 , O b (C 1 -C 3 )perfluoroalkyl, (C 0 -C 6 )alkylene-S(O) m R a , C(O)R a , (C 0 C 6 )alkylene-CO 2 R a , C(O)H, (C 0 -C 6 )alkylene-CO 2 H, C(O)N(R b ) 2 , and S(O) 2 N(R b ) 2 ; said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and alkylene is optionally substituted with up to three substituents selected from R b , OH, (C 1 -C 6 )alkoxy, halogen, CO 2 H, CN, (O)C═O(C 1 -C 6 )alkyl, oxo, and N(R b ) 2 ;

R 3 is selected from: (C 1 -C 6 )alkyl, amino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl amino, hydroxy (C 1 -C 6 )alkyl, OH and NH 2 ;

two R 4 s are combined to form an alkylene diradical selected from: —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —and —CH 2 CH 2 CH 2 CH 2 —;

R a is selected from: (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, and aryl; said alkyl, cycloalkyl, and aryl is optionally substituted with one or more substituents selected from R 3 ;

R b is independently selected from: H, oxo, OH, (C 1 -C 6 )alkyl, aryl, (C 3 -C 6 )cycloalkyl, (C═O)O(C 1 -C 6 )alkyl, C═O(C 1 -C 6 )alkyl and S(O) 2 R a ; said alkyl, cycloalkyl, or aryl is optionally substituted with one or more substituents selected from R 3 ;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound according to claim 1 , as illustrated by Formula II:

wherein all other substituents and variables are as defined in claim 1 ;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. The compound according to claim 2 wherein:

R 1 is selected from: H, halo, OH, oxo, O b (C 1 -C 6 )alkyl, CN, NO 2 , NH 2 , and hydroxy(C 1 -C 6 )alkyl;

R 2 is selected from: H, halo, CF 3 , CN and O b (C 1 -C 6 )alkyl;

and all other substituents and variables are as defined in claim 2 ;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. A compound which is selected from:

4-[2-(1-phenylcyclopropyl)-1,3-thiazol-5-yl]benzonitrile;

4-(3-methoxyphenyl)-2-(1-phenylcyclopropyl)-1,3-thiazole;

5-methyl-2′-(1-phenylcyclopropyl)-4,4′-bi-1,3-thiazol-2-amine;

2′-(1-phenylcyclopropyl)-2,5′-bi-1,3-thiazole;

3-[2-(1-phenylcyclopropyl)-1,3-thiazol-4-yl]benzonitrile;

3-[2-(1-phenylcyclopropyl)-1,3-thiazol-4-yl]pyridine;

4-{2-[1-(2,4,6-trifluorophenyl)cyclopropyl]-1,3-thiazol-4-yl}benzonitrile;

4-{2-[1-(2,4-difluorophenyl)cyclopropyl]-1,3-thiazol-4-yl}benzonitrile;

4-{2-[1-(2,6-difluorophenyl)cyclopropyl]-1,3-thiazol-4-yl}benzonitrile;

4-{2-[1-(4-fluorophenyl)cyclopropyl]-1,3-thiazol-4-yl}benzonitrile;

5-[2-(1-phenylcyclopropyl)-1,3-thiazol-4-yl]pyridine-2-carbonitrile;

4-[2-(1-phenylcyclopropyl)-1,3-thiazol-4-yl]-1lambda˜5˜-pyridin-1-ol;

4-(3,4-dihydroxyphenyl)-2-(1-phenylcyclopropyl)-1,3-thiazole;

4-[2-(1-phenylcyclopropyl)-1,3-thiazol-4-yl]pyridin-3-ol;

4-[2-(1-phenylcyclopropyl)-1,3-thiazol-4-yl]phenol;

3-[2-(1-phenylcyclopropyl)-1,3-thiazol-4-yl]phenol;

{3-[2-(1-phenylcyclopropyl)-1,3-thiazol-4-yl]phenyl}methanol;

4-{2-[1-(2,4,6-trifluorophenyl)cyclopropyl]-1,3-thiazol-4-yl}pyridine;

4-{2-[1-(4-bromophenyl)cyclopropyl]-1,3-thiazol-4-yl }pyridine;

4-{2-[1-(4-chlorophenyl)cyclopropyl]-1,3-thiazol-4-yl}pyridine;

4-{2-[1-(4-fluorophenyl)cyclopropyl]-1,3-thiazol-4-yl}pyridine;

4-{2-[1-(2-methylphenyl)cyclopropyl]-1,3-thiazol-4-yl}pyridine;

4-{2-[1-(2-bromophenyl)cyclopropyl]-1,3-thiazol-4-yl}pyridine;

4-(2-{1-[3-(trifluoromethyl)phenyl]cyclopropyl}-1,3-thiazol-4-yl)pyridine;

4-{2-[1-(3-chlorophenyl)cyclopropyl]-1,3-thiazol-4-yl}pyridine;

4-{2-[1-(2-fluorophenyl)cyclopropyl]-1,3-thiazol-4-yl}pyridine;

4-[1-(4-pyridin-4-yl-1,3-thiazol-2-yl)cyclopropyl]benzonitrile;

2-chloro-4-[2-(1-phenylcyclopropyl)-1,3-thiazol-4-yl]pyridine;

4-{2-[1-(3-methylphenyl)cyclopropyl]-1,3-thiazol-4-yl}pyridine;

4-{2-[1-(2,6-difluorophenyl)cyclopropyl]-1,3-thiazol-4-yl}pyridine; and

4-{2-[1-(2,4-difluorophenyl)cyclopropyl]-1,3-thiazol-4-yl}pyridine;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. The trifluoroacetic acid salt of a compound according to claim 1 which is:

4-[2-(1-phenylcyclopropyl)-1,3-thiazol-5-yl]benzonitrile;

or stereoisomer thereof.

6. A compound according to claim 4 which is selected from:

4-[2-(1-phenylcyclopropyl)-1,3-thiazol-5-yl]benzonitrile; and

5-[2-(1-phenylcyclopropyl)-1,3-thiazol-4-yl]pyridine-2-carbonitrile;

or a pharmaceutically acceptable salt or stereoisomer thereof.

7. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of claim 1 .